TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04547140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT04547140
Drug: Standard Medical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMT
Study: NCT05964985
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the induction of anesthesia, normal saline is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
Study: NCT04655508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For children between 6 to 11 years (\< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (\> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
Study: NCT04531748
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.
Study: NCT05547880
Drug: [11C]ER176
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain PET with \[11C\]ER176. \[11C\]ER176 is a PET ligand that images TSPO.
Study: NCT06470451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
Study: NCT04322669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized in ratio of 1:1 to receive placebo matched to Pidotimod, once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
Study: NCT05449444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04643327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intervention will be maize-starch filled capsules with identical physical features to the active capsules.
Study: NCT05930171
Drug: Postoperative conventional analgesia in form of Acetaminophen
Normalized name: acetaminophen / phenyltoloxamine citrate Oral Capsule [Dolorex brand of acetaminophen-phenyltoloxamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative conventional analgesia in form of acetaminophen 15 mg/kg/6hrs
Study: NCT06106880
Drug: Wintergreen Throat Spray and Aspirin Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Aspirin in a 325mg tablet
Study: NCT06106880
Drug: Aspirin Throat Spray and Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The liquid spray contained 6mg dissolved acetyl salicylic acid per dose, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients.
Study: NCT06796699
Drug: GH56 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH56 capsule for oral administration at specified doses on scheduled days.
Study: NCT06750276
Drug: AZD2389
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of AZD2389 or placebo will be administered orally.
Study: NCT05742256
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control group (SF group): sufentanil 2ug/kg + flurbiprofen + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
Study: NCT04739293
Drug: ON123300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ON 123300 hard gelatin capsules
Study: NCT05556460
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will continue to be managed on medical therapy, per physician discretion
Study: NCT03052569
Drug: RXDX-105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsules
Study: NCT05183334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05160402
Drug: IGM-6268
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator
Study: NCT05160402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT06301529
Drug: Invokana Pill
Normalized name: Invokana Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg and 150 mg doses, taken every day and every-other day, respectively.
Study: NCT05320861
Drug: [14C]SJP-0008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of \[14C\]SJP-0008
Study: NCT05018702
Drug: ARX788
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
Study: NCT04283097
Drug: KPG-818
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 4 planned dose level (cohorts) of KPG-818 will be explored: 2, 3, 4 and 5mg. Each dose of KPG-818 will be administered orally with approximately 240 ml of water daily, and used as a single agent in subjects with selected hematological malignancies (or in combination with dexamethasone weekly for MM), according to specific dosing schedule in each treatment cycle until disease progression, unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met. The treatment of study is divided into 6 cycles.
Study: NCT05415072
Drug: DYP688
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent DYP688
Study: NCT04780672
Drug: Molixan
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational drug in this study is Molixan in the dosage form of 30 mg/ml solution for intravenous and intramuscular injection. Against the background of standard therapy: Molixan® at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
Study: NCT04780672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be used as a comparator drug and will be an analogue of the investigational drug without active substance. Against the background of standard therapy: Placebo at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
Study: NCT06608459
Drug: PEX010-Assisted Therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigational medicinal product PEX010 is a capsule for oral administration that contains the drug substance PYEX.
Study: NCT05205304
Drug: D'Oxyva
Approvals — FDA: no, EMA: no, PMDA: no
Description: The transdermal CO2 was administered via non-invasive vaporization technique accommodated by deoxyhemoglobin vasodilator (D'Oxyva)
Study: NCT04978337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to rilematovir will be administered orally.
Study: NCT04824898
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Statins are first known as drugs that decrease the cholesterol level by inhibiting hydroxy-methyl-glutaryl co-enzyme-A reductase as they improve the lipid profile and help in the treatment of many cardiac diseases and has a role in osteoblasts diffrentiation
Study: NCT05230797
Drug: Zinc oxide Propolis
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibacterial and anti-inflammatory
Study: NCT05230797
Drug: Zinc Oxide-Eugenol Cement
Normalized name: Eugenol
DrugBank: Eugenol (DB09086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antimicrobial and antiseptic
Study: NCT06519981
Drug: HRS-9231or matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-9231 injection or matching placebo will be administered through IV injection.
Study: NCT02942706
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin+LV5FU2
Study: NCT05886088
Drug: LID104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT05307679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral placebo
Study: NCT04872387
Drug: BAY2586116
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal administration
Study: NCT04872387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT06521190
Drug: ACOU085 (bimokalner)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transtympanic injection
Study: NCT06521190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transtympanic injection
Study: NCT05582278
Drug: D-TACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
Study: NCT05582278
Drug: HAIC
Normalized name: Hepatic Arterial Infusion Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 100 mg/m2 infusion for 2 hours; calcium levofolinate, 200 mg/m2 infusion for 1 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
Study: NCT00002029
Drug: Fat Emulsion 2%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002029
Drug: Fat Emulsion 20%
Normalized name: Fat Emulsion 20% Intravenous Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06720506
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl will be given intrathecal with dose 10-20ug
Study: NCT05930314
Drug: CNCT19 cell injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukapheresis and manufacturing of CNCT19: enrolled subjects will undergo a leukapheresis to target a yield of \> 1x 10\^9 mononuclear cells~* Lymphodepleting chemotherapy i. Fludarabine 25 to 30 mg/m2, once daily for 3 days ii. Cyclophosphamide 500 mg/m2, once daily for 3 days~* CNCT19 administration i. 0.25 to 0.5 x 10\^8 CAR-positive viable T cells
Study: NCT05454020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
Study: NCT06720805
Drug: Pentabiocel
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires.
Study: NCT06720805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires.
Study: NCT04944784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet
Study: NCT05672498
Drug: Traditional Chinese Medicine Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The TCM Treatment Group：The patient are given a traditional Chinese medicine formulation, taking 150 ml of liquid medicine every morning and evening for 7 days.
Study: NCT05000411
Drug: Compound Danshen Dropping Pills (CDDP)
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in this group are treated with 20 tablets of Compound Danshen Dropping Pills (CDDP) before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI.
Study: NCT05000411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in this group take 20 tablets of placebo before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI .
Study: NCT05733000
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive IV
Study: NCT04903912
Drug: Medical treatment according to current guidelines
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic drugs, lipid-lowering drugs, antihypertensive drugs, and pharmacotherapy to increase walking capacity according to current guidelines
Study: NCT04717362
Drug: Natesto Nasal Product
Normalized name: Natesto Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasally administered exogenous 4.5% testosterone gel, administered from a non-pressurized, manual pump dispenser equipped with a specialized nasal applicator which administers 125uL (5.5mg of testosterone).
Study: NCT04520685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
Study: NCT05624229
Drug: Proton Pump Inhibitors
Normalized name: Proton pump inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI infusion continued to use for 5 days in experimental group
Study: NCT05624229
Drug: No Proton Pump Inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI infusion stopped in standard group after endoscopy.
Study: NCT05246618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex-vivo infusion
Study: NCT06453304
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracanal medication
Study: NCT06453304
Drug: Leddermix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracanal medication
Study: NCT06453304
Drug: Glycirrhizin
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracanal medication
Study: NCT06217666
Drug: PCX-12
Normalized name: PCxx Neutral Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment combining radiation therapy with PCX12
Study: NCT05647122
Drug: AZD9592
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varying doses of AZD9592
Study: NCT05647122
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT05840159
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.
Study: NCT05594147
Drug: Non-TKIs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
Study: NCT05582421
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intracanal medication
Study: NCT05132660
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill of similar size/shape
Study: NCT05582629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days
Study: NCT04967521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally twice a day. Each cycle is 28 days.
Study: NCT05609682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given for two weeks after surgery
Study: NCT04710875
Drug: Na-lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT05343819
Drug: AON-D21
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AON-D21 is a PEGylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
Study: NCT05343819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic glucose solution identical in appearance to AON-D21.
Study: NCT05144854
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05626920
Drug: Disulfiram 250 mg
Normalized name: disulfiram 250 MG
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram treatment
Study: NCT05626920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment
Study: NCT06269900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection is given as a slow injection or infusion (intravenous drip) into the veins.
Study: NCT06646354
Drug: Ezetimibe/Rosuvastatin/Candesartan/Amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, QD, 8 weeks
Study: NCT06646354
Drug: Candesartan/Rosuvastatin/Ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, QD, 8 weeks
Study: NCT05150457
Drug: BNA035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody
Study: NCT04741646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match Ferric Citrate tablets
Study: NCT03707418
Drug: Heparin Sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Heparin titrated to Partial ThromboplastinTime (PTT) levels
Study: NCT05145413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsules
Study: NCT06047379
Drug: FOLFIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
Study: NCT05082233
Drug: SHR7280 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group A:SHR7280 tablets ; 300mg BID； Treatment group B:SHR7280 tablets ; 200mg BID； Treatment group C:SHR7280 tablets ; 200mg QD； Treatment group D:SHR7280 tablets ; 400mg BID；
Study: NCT00231517
Drug: topical opiod
Normalized name: Morphinan derivatives, opiod analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06612411
Drug: Dead B. subtilis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules, 3 times a day, orally taken for one month
Study: NCT06612775
Drug: Test drug CB03-154 5mg group
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB03-154 tablet (5mg/tablet) once daily.
Study: NCT06612775
Drug: Test drug CB03-154 10mg group
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two CB03-154 tablets (5mg/tablet) once daily.
Study: NCT06612775
Drug: Test drug CB03-154 20mg group
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four CB03-154 tablets (5mg/tablet) once daily.
Study: NCT06612775
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four Placebo tablets once daily.
Study: NCT01514942
Drug: Folic acid, vit B12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
Study: NCT05758818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of placebo on Day 1, Day 8 or Day 15 of part 2
Study: NCT04859946
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05289375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sample will be taken from all participants in group P following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory (as in group T). After 1 month from the collection of the sample, the laboratory will send it in a container/dispenser (with the same appearance in both groups). The content in group P will receive a placebo in the same dosage and temporality as group T, it will be the same except for the active ingredient, that is, only thimerosal, methylcellulose, sodium chloride and orange essence.
Study: NCT05621668
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV (vein)
Study: NCT04882098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo as SC injection.
Study: NCT02988245
Drug: Geneticure Panel for HTN therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using either Genetics (Geneticure for HTN multi-gene panel) or JNC-8 guidelines for prescribing for patients with hypertension